Mobile

Study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infa...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-001544-11

Study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immunogenicity of GSK Biologicals’ HRV liquid vaccine versus placebo, in terms of anti-rotavirus Immunoglobulin A (IgA) antibody seroconversion at Month 3 (i.e. Visit 4), when administered concomitantly with the second and third routine EPI immunization

Critère d'inclusion

  • Healthy Volunteers

Liens